Tuck S.A.,Uptake Medical |
Lopes-Berkas V.,American Preclinical Services |
Beam S.,Preclinical Pathology Consulting Services |
Anderson J.C.,Uptake Medical
International Journal of COPD | Year: 2012
Clinical studies indicate the potential of bronchoscopic thermal vapor ablation to result in clinically relevant improvements in severe chronic obstructive pulmonary disease patients with upper lobe-predominant emphysema. However, the mechanisms by which vapor ablation results in lung volume reduction are not fully known. This study determined the 3-month safety and efficacy of vapor ablation in a canine model of emphysema and described the histopathological changes in the lung. The cranial lobes of papain-exposed dogs were treated with a vapor dose of ten calories per gram of lung tissue (n = 8) or were sham treated (n = 3). Safety was monitored peri- and postoperatively for 3 months. Animals were then sacrificed, estimates of lung volume reduction performed, and the lungs processed for histology. Vapor ablation was associated with an average of 20% volume reduction of the treated lobes and an absence of serious adverse events. The amount of lobar volume reduction was correlated with the amount of fibrosis and atelectasis in the treated lobe. Bronchoscopic thermal vapor ablation at a dose of 10 cal/g results in lobar volume reduction associated with remodeling of the targeted tissue characterized by mature collagen formation in the absence of major adverse events. © 2012 Tuck et al, publisher and licensee Dove Medical Press Ltd.
Uptake Medical | Date: 2013-01-16
This invention relates to the treatment of a patients lung, for example, a lung exhibiting chronic obstructive pulmonary disease (COPD) and in particular to a device for affecting lung volume reduction, preferably for achieving acute or immediate lung volume reduction following treatment. The lung volume reduction is effected by delivering a condensable vapor at a temperature above body temperature to the desired regions of the patients lung to damage tissue therein. Blood flow and air flow to the damaged tissue region is essentially terminated, rendering the target region non-functional. Alternative energy sources may be used to effect the thermal damage to the lung tissue.
News Article | October 2, 2015
AMSTERDAM--(BUSINESS WIRE)--Medical technology innovator Uptake Medical announced today that patients with severe emphysema who underwent bronchoscopic lung volume reduction performed with the company’s InterVapor® targeted therapy experienced statistically significant and clinically meaningful benefits in both lung function and quality of life, according to data presented by Prof Dr Med Ralf Eberhardt, an interventional pulmonologist of the Thoraxklinik in Heidelberg, Germany at the European Respiratory Society (ERS) annual meeting in Amsterdam. Prof Eberhardt, an investigator in the STEP-UP clinical study -- a randomized, controlled, multi-center, multi-national trial that involved patients from 13 centers located in Europe and Australia -- reported that InterVapor patients’ FEV1 (lung function) improved 14.7 percent at the six-month mark, while their health-related quality of life (St. George’s Respiratory Quotient or SGRQ-C), showed a 9.7 point improvement. Both of these metrics were statistically significant and exceeded ATS/ERS standards for clinically meaningful improvement. The STEP-UP study was designed to evaluate the safety and performance of the InterVapor system in addition to the optimal medical standard therapy in improving lung performance and quality of life of patients with severe emphysema. The InterVapor system uses heated water vapor to achieve bronchoscopic lung volume reduction in patients with heterogeneous upper lobe emphysema, and was developed by the privately held Uptake Medical. The system recently received Conformité Européene (CE) Mark, allowing commercial sale in Europe. According to Prof Felix Herth, interventional pulmonologist of the Thoraxklinik and co-principal investigator of the STEP-UP study, “The STEP-UP results affirm InterVapor’s safety and effectiveness and represent an important milestone in bronchoscopic intervention. For the first time, we have the option to safely treat patients’ most diseased segments and preserve the less diseased segments, while enhancing both their lung function and quality of life.” Professor Greg Snell, STEP-UP co-principal investigator from The Alfred Hospital in Melbourne, Australia, said, “The gradual natural process of volume reduction that occurs as a result of InterVapor resulted in no pneumothorax in patients 30 days post-treatment. And, since InterVapor requires no implant, patients’ risk of long-term complications is also eliminated. InterVapor is a safe, simple procedure that offers an option to treat severe emphysema patients over time as their disease progresses.” “Uptake Medical is pleased with these promising clinical results, which show that InterVapor plays an important role in offering progressive treatment options for emphysema patients. The technology has now been proven in a randomized clinical trial to improve patients’ lung function and quality of life during the natural progression of this debilitating disease,” said King Nelson, president and CEO of Uptake Medical. Uptake Medical is a privately held company focused on the treatment of lung cancer and emphysema without the risks of surgery and implants or the toxicity of radiation. InterVapor, Uptake’s proprietary targeted vapor ablation technology that received CE Mark approval in 2015, applies energy with heated water vapor via a standard bronchoscope to the lungs. In the 15-minute procedure, lung tissue ablation is performed on the more diseased lung segments. The healthier segments are preserved to provide lung function and quality of life improvements in emphysema patients and to provide potential future targets as the disease inevitably progresses. The InterVapor platform is now being tested and validated as a possible treatment for lung cancer tumors in a first-in-human study of regional lung tumor ablation in patients with early stage lung cancer and lung metastases. The outside-in bronchoscopic approach eliminates the need for percutaneous access or the need to pierce the tumor in a 10-second ablation during a 15-minute procedure. Founded in 2005, Uptake Medical is located in Tustin, California.
News Article | July 28, 2010
Compared to the handful of “under the radar” deals we had to report on in our May roundup, the month of June was buzzing with deals, both small and large, for Seattle-area tech and biotech companies. Normally we publish our “under the radar” roundup for regional deals worth less than $1 million in a monthly post. However, for the first time this month we are combining our normal “under the radar” list with deals worth more than $1 million, creating one comprehensive report of all local equity deals. This information is based on data provided by New York-based private company intelligence platform CB Insights, and our own past coverage. Despite the fact that deals of all sizes are represented on the June list, the majority were for less than $1 million. And contrary to what you might assume, given that Seattle is a hub for many areas of information technology, healthcare and energy/utilities companies dominated the roundup. Of the $104.3 million in venture dollars raked in through 20 equity deals in June, Washington companies in the healthcare sector pulled in $41.1 million, while those in energy and utilities brought in $35.8 million. The third leading sector was computer hardware and services, which raised $15 million in investments last month. Internet startups came in fourth at $4.9 million, and industrial startups followed up with $3.95 million, while financing for business products and services, software, and video startups all trailed behind. We reported on the majority of June venture investments as the news broke, including the $40 million nabbed by Seattle-based Calistoga Pharmaceuticals, amounting to the biggest Washington venture deal of 2010 thus far. Not far behind was three-year-old Intellectual Ventures spinout, Bellevue,WA-based TerraPower, which brought in $35 million in Series B funding for further development of its traveling wave nuclear reactor. Other notable deals include the $11 million Seattle software developer Opscode earned in Series B led by Battery Ventures, and the $4 million raised by cloud storage and data protection Seattle startup Symform. However, a number of interesting deals slipped under our radar. Here are a few that I found interesting: Bellevue, WA-based online collaboration and file sharing software developer OneHub raised $750,000 in equity. The three-year-old company, which provides cloud-based software-as-a-service for thousands of companies, raised $1.3 million in Series A financing led by local venture capital firm Ignition Partners back in October. Liberty Lake, WA-based Demand Energy Networks, which is developing technology to help energy providers manage their electricity supply, brought in $650,000. The company, founded in 2008, has developed a tool called the Demand Shifter, which allows a variety of businesses and consumers to store electricity at distributed end points during times of low demand, and control and dispatch it as it’s needed. Seattle-based medical device developer Uptake Medical raised $600,000 in equity in June. The interventional pulmonology company then followed that up with another $17.5 million in a Series B round led by Maverick Capital this month. The only video game startup on the list, Redmond, WA-based Novel, raised $550,000 in equity. The 20-person startup plans to change the gaming industry and corporate culture as we know them by applying massively multiplayer online (MMO) gaming techniques to create new kinds of games and business simulations for companies. Seattle-based Liquid Light brought in $200,000 in equity financing. The early-state energy startup is expanding on the research of Princeton University professor Andrew Bocarsly to develop highly efficient technology for converting carbon dioxide to fuels and industrial chemicals without using biological feedstocks. this month. The only video game startup on the list, Redmond, WA-based Here’s the full list of June’s equity-based deals, both under the radar and on it: June also saw a few startups raising cash through deals based on debt, options, and/or warrants, rather than equity. Those three transactions, worth a combined $1.64 million, are listed below. Thea Chard is a correspondent for Xconomy Seattle. You can e-mail her at email@example.com or follow her on Twitter at http://twitter.com/theachard. Follow @
News Article | August 12, 2015
TUSTIN, Calif.--(BUSINESS WIRE)--Uptake Medical announced today that it has received CE Mark allowing the commercial sale of its InterVapor system in Europe. InterVapor uses heated water vapor to achieve bronchoscopic lung volume reduction in patients with heterogeneous upper lobe emphysema. According to The Organisation for Economic Co-operation and Development, more than 23 million people in Europe suffer from emphysema, a debilitating and progressive condition that affects the respiratory system1. “The traditional treatment options for severe emphysema patients have been very limited which is why we have remained committed over the past decade to finding a more meaningful treatment alternative for this progressive disease,” said King Nelson, President and CEO of Uptake Medical. “Gaining CE Mark is a major milestone for our company, but more importantly, represents new hope for emphysema patients. We are eager to begin the commercial launch of InterVapor in Europe allowing more interventional pulmonologists to begin using the system in the months ahead.” The CE Mark follows results of the STEP-UP study, a prospective, multi-center, multi-national, randomized-controlled study that was completed in late 2014. STEP-UP, which involved patients from 13 centers in Europe and Australia, was designed to evaluate the safety and performance of the InterVapor system in addition to the optimal medical standard therapy in improving lung performance and quality of life of patients with severe emphysema. The STEP-UP trial results will be reported at the European Respiratory Society meeting in Amsterdam in late September 2015. According to Prof Dr. Med Felix Herth, STEP-UP’s co-principal investigator from ThoraxKlinik in Heidelberg, Germany, “Being granted the CE Mark validates for Uptake Medical the merits of our clinical hypothesis to have for the first time an option where we can treat the most diseased segments and preserve the less diseased segments.” Professor Greg Snell, STEP-UP co-principal investigator from The Alfred Hospital in Melbourne, Australia, said, “InterVapor provides a new way to offer non-surgical treatment to severe emphysema patients over time as the disease progresses.” “InterVapor offers emphysema patients who have exhausted their other medical support options another potential solution to improve their lung function and quality of life, and we look forward to making this technology more widely available to patients across Europe,” Nelson said. Uptake Medical is a privately held company focused on the treatment of lung cancer and emphysema without the risks of surgery and implants or the toxicity of radiation. InterVapor, Uptake’s proprietary targeted vapor ablation technology that received CE Mark approval in 2015, applies energy with heated water vapor via a standard bronchoscope to the lungs. In the 15-minute procedure, lung tissue ablation is performed on the most diseased lung segments. The healthier segments are preserved to provide lung function and quality of life improvements in emphysema patients and to provide potential future targets as the disease inevitably progresses. The InterVapor platform is now being tested and validated as a possible treatment for lung cancer tumors in a first-in-human study of regional lung tumor ablation in patients with early stage lung cancer and lung metastases. The outside-in bronchoscopic approach eliminates the need for percutaneous access or the need to pierce the tumor in a 10-second ablation during a 15-minute procedure. Founded in 2005, Uptake Medical is located in Tustin, California.
News Article | October 9, 2009
Seattle-based Uptake Medical has secured $1.2 million in a second closing of an equity financing, meaning it has raised a total of $4.6 million so far in a round that could be worth as much as $13.3 million if the company achieves certain milestones, says CEO King Nelson. The company is developing a minimally invasive technique for treating chronic lung diseases by using hot vapor to seal off damaged parts of lung so air doesn’t get trapped there. The company is starting larger trials to win clearance to start marketing its device in Europe.
News Article | December 15, 2008
Uptake Medical, a Seattle-based medical device company, has raised $3 million to carry out a pair of small clinical trials that could show it has a viable technique for treating emphysema, and other deadly lung-obstructing diseases. The company got the cash as a “bridge” financing to carry out trials in Australia and Germany, which should help it get to the next step of raising a Series B round in 2009, says CEO King Nelson. The company, which has 20 employees in Belltown, raised the capital from all of its previous investors: Prism VentureWorks, Onset Ventures, Arboretum Ventures, GBS Venture Partners, Affinity Capital, and WRF Capital, Nelson says. Uptake is working on a technique that would let doctors thread a catheter to a damaged part of lung where air gets in, but can’t get out. Uptake’s idea is to deliver a burst of steam water vapor that scars and seals shut airways that lead to the bad part of the lung, allowing the patient to breathe better with the healthy regions of his or her lung. This is a different approach from its regional rival, Redmond, WA-based Spiration, which is developing a tiny valve that can be implanted in the lung to block off air to the diseased part. “The encouraging sign is that our existing investors are supportive of what we’re doing,” Nelson says. “As you know, the economic environment is very tough now.” The world of minimally-invasive devices for emphysema has taken a couple steps forward, and one step back since I profiled Uptake’s effort back in July. Spiration won FDA approval of its valve device in a narrow group of patients who suffer prolonged air leaks after they’ve had surgery to remove a diseased part of lung. Another competitor, Broncus Technologies of Mountain View, CA, raised $38 million in a new round of funding earlier this month. But a third competitor, Redwood City, CA-based Emphasys Medical, failed to get a recommendation for its product from an FDA advisory panel earlier this month. Uptake’s trial in Australia is enrolling 30 patients, and the one in Germany is recruiting about 20, Nelson says. Results should start rolling in during February, with more follow-up data coming three to six months later in 2009. He plans to have talks with investors next month at the JP Morgan Healthcare conference in San Francisco about what to expect from these trials, at a higher dose. If the Australian and Germany trials go well, they should lay the groundwork for a larger round of funding in 2009, and the first trial in the U.S., he says. The failure of Emphasys should help Uptake learn how to best design its trials to satisfy the FDA’s standards for clinical benefit, and get the statistical significance to prove it’s no fluke, Nelson says.
News Article | May 20, 2009
Uptake Medical, the Seattle-based company developing minimally invasive technology to treat emphysema, has raised $3.1 million in a debt financing, according to a regulatory filing. Uptake is developing a device that’s supposed to seal off access to diseased parts of the lung where air gets trapped, without leaving any implantable device behind. It is competing with Redmond, WA-based Spiration, among others. The latest round is in addition to the $3 million bridge financing the company raised for its clinical trials in December.
News Article | May 20, 2009
Uptake Medical Corporation is a Seattle-based medical device company dedicated to improving the lives of patients suffering from emphysema and other types of chronic obstructive pulmonary diseases (COPD).